BÜHLMANN IBDoc® Archives - Page 3 of 3 - Buhlmann Diagnostics Corp

Tag: BÜHLMANN IBDoc®

Calprotectin Testing Goes Mobile

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article from Amanda Appleton, the Product Manager for Calprotectin at BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article     “App technology has the ability not only to improve the health of patients but
Continue Reading

BUHLMANN – LabSense News Spring 2018 Edition

In this “Summer Edition” we are pleased to share the launch of the of Quantum Blue® Adalimumab assay as well as announce some recent enhancements to the Quantum Blue® Infliximab assay. We also make mention of the upcoming meetings…

Continue Reading

IBDoc and Me

Health Canada Licence: 98903, Device class: 3  IBDoc® is not available for sale in the US. Read perspectives and insights from a patient from the UK who has been using IBDoc®  since last October and is trying this new tool to monitor his Crohn’s Disease.  He has been documenting his experiences in a blog to share his
Continue Reading

Join Us at CSCC 2018 in Ottowa!

Canadian Society for Clinical Chemists (CSCC) 2018 BUHLMANN Diagnostics Corp  Booth: #410 June 03 - 06, 2018 | Fairmont Château Laurier Hotel. | Ottawa, ON Learn More Come by our booth to get an update on our Calprotectin,Therapeutic Drug Monitoring, Chemistry, Neuroimmunology, and Cellular Allergy portfolios Calprotectin and TDM: IBDoc®, the ONLY in-vitro diagnostic POC and home testing
Continue Reading

BUHLMANN LabSense News Winter 2018 Edition

BUHLMANN Diagnostics Corp is proud to release the sixth edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. Check Out LabSense News Today! What's New Introducing BAT in Food Allergy Webinar recording and eBook by Dr. Alexandra Santos as well as two new IBDoc®  Posters
Continue Reading

Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®

BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®.  CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Continue Reading